Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 12/20 | 0.74 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.64 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13832500 | 0.85 | MTNR1B (0.67) | MTNR1BMTNR1APGRACACBSMN1; SMN2 | |
| SCHEMBL1979299 | 0.84 | MTNR1B (0.52) | MTNR1BMTNR1APGRMAPK1SMN1; SMN2 | |
| SCHEMBL17350112 | 0.84 | MTNR1B (0.52) | MTNR1BMTNR1APGRMAPK1SMN1; SMN2 | |
| SCHEMBL13268428 | 0.84 | MTNR1B (0.65) | MTNR1BMTNR1APGRMAPK1ACACB | |
| SCHEMBL1980614 | 0.83 | MTNR1B (0.80) | MTNR1BMTNR1APGRARTSHR | |
| SCHEMBL11637763 | 0.83 | MTNR1B (0.80) | MTNR1BMTNR1APGRARTSHR | |
| SCHEMBL25386654 | 0.81 | MTNR1B (0.59) | MTNR1BSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL25386658 | 0.81 | MTNR1B (0.59) | MTNR1BSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL4630369 | 0.78 | MTNR1B (1.00) | MTNR1BMTNR1APGRARTSHR | |
| SCHEMBL13721650 | 0.78 | MTNR1B (0.67) | MTNR1BMTNR1APGRSMN1; SMN2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10058551-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-08-28 | — | — | US | disclosed |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-9849131-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20170065585-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2017-03-09 | — | — | US | disclosed |
| EP-2509961-B1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LTD (GB) | 2016-03-09 | — | — | EP | disclosed |
| US-20160058737-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-9216967-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | MTNR1B 1903/4885MTNR1A 2267/4885PGR 3975/4885 |
| US-20170065585-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | MTNR1B 1903/4885MTNR1A 2267/4885PGR 3975/4885 |
| US-20160058737-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | MTNR1B 1903/4885MTNR1A 2267/4885PGR 3975/4885 |
| US-10058551-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | MTNR1B 1903/4885MTNR1A 2267/4885PGR 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.